Beta Bionics (BBNX) Liabilities and Shareholders Equity (2023 - 2026)

Beta Bionics has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $304.4 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $304.4 million, down 9.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 165.18% YoY), and the FY2025 annual result was $328.7 million, up 119.68% from the prior year.
• Liabilities and Shareholders Equity came in at $304.4 million for Q1 2026 at Beta Bionics, down from $328.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $338.0 million in Q1 2025 to a low of $110.0 million in Q4 2023.
• The 4-year median for Liabilities and Shareholders Equity is $328.7 million (2025), against an average of $270.1 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 119.68% in 2025 and dropped 9.94% in 2026, its largest moves.
• Beta Bionics' Liabilities and Shareholders Equity stood at $110.0 million in 2023, then soared by 35.99% to $149.6 million in 2024, then surged by 119.68% to $328.7 million in 2025, then declined by 7.4% to $304.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $304.4 million (Q1 2026), $328.7 million (Q4 2025), and $330.0 million (Q3 2025), per Business Quant data.